Navigation Links
Cumberland Pharmaceuticals Appoints Rick S. Greene as Vice President, Finance & Accounting
Date:4/4/2011

NASHVILLE, Tenn., April 4, 2011 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Rick S. Greene, a long-time financial advisor to the Company, has been appointed interim Vice President, Finance & Accounting effective April 5, 2011.  Mr. Greene has more than 20 years of experience in financial management and reporting.  He previously served as Chief Financial Officer at Surgical Alliance Corporation, a specialty hospital company, and Director of Financial Operations at Phycor, Inc., a publicly held physician management company.  He also has held positions at the national accounting firms Ernst & Young and Crowe Horwath.

Mr. Greene is the Market Leader for Crowe Horwath's Tennessee healthcare practice, where he has developed and led a financial advisory team serving private equity firms, technology, pharmaceutical and other healthcare companies.  Mr. Greene and his team supported Cumberland's accounting department in the preparation of the Company's Initial Public Offering, as well as Cumberland's ongoing financial statement preparation and SEC reporting.  

David L. Lowrance, who has been serving as Cumberland's Vice President, Finance & Accounting and Chief Financial Officer, will transition out of that role as he pursues interests outside of the Company following his acceptance of an appointment at a private healthcare company.

"We welcome and support Rick in his new role and are fortunate that we are able to draw on his depth of knowledge and experience with our Company," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "We are grateful for Dave's contributions to the Company and wish him well in his new endeavors. We believe that this is an appropriate time for such a transition, following the completion and filing of our 2010 audited financials as well as the conclusion of our first Sarbanes-Oxley audit."

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland, please visit the Company's website at www.cumberlandpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or a failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's 2010 Annual Report on Form 10-K filed with the SEC on March 11, 2011. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.


'/>"/>
SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
5. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
6. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... PUNE, India , Jan. 17, 2017  Market Research Future ... Global Endoscopy Devices Market is expected to reach USD 33.6 million ... 2016. Market Highlights ... The Global Endoscopy Devices Market has been examined as ... rate. Globally there is huge demand for endoscopy device in various ...
(Date:1/17/2017)... , Jan. 17, 2017 Following an ... today praised the Food and Drug Administration,s (FDA,s) ... Human Drug Products by Pharmacies and Outsourcing Facilities." ... proposed limitation on pre-packaging -- which would have ... costs to long term care (LTC) pharmacies.  ...
(Date:1/17/2017)... Mich. , Jan. 17, 2017   ... in billing and practice management for the anesthesia ... medical marijuana, which remains a "clinical conundrum" (as ... and chronic pain practitioners to think carefully before ... A 395-page report by the National Academies of ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Achieve TMS ... is opening a new office in San Clemente, California this month. Achieve TMS ... Southern California, successfully treating individuals struggling with major depression. Depression impacts over 15 ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... A prescription ... winners of the fourth Cradle to Cradle Product Design Challenge , the ... in a series of six circular design challenges scheduled to run through early 2018. ...
(Date:1/17/2017)... Los Gatos, CA (PRWEB) , ... January 17, 2017 , ... ... today announced the results of a double blind clinical study for its dental gel ... to a leading national brand of toothpaste containing triclosan. The study was conducted at ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Many people make New Year’s resolutions or renew ... Mondavi is making it easier for people who want to kick off 2017 with ... and existing patients. , These special offers include: , , ...
(Date:1/16/2017)... , ... January 16, 2017 , ... California Southern University ... has served on CalSouthern’s Board of Trustees and as a core faculty member, teaching ... has been a professor of psychology at Pepperdine University, where he earned his Doctor ...
Breaking Medicine News(10 mins):